The Biotech Bear Market: Is it over?

On July 13th, 2015, the iShares Nasdaq Biotechnology ETF (ticker: IBB) peaked at just under $400 per share. A little less than a year later, the popular biotech exchange traded fund traded at $249 per share—down 37 percent from its all-time high. The combination of an over-extended sector and the political rumblings in D.C. threatening…

0 comments

A Primer on Orphan Drugs

One of the most intriguing areas in today’s pharmaceutical sector is the topic of orphan drugs. Orphan drugs are drugs that are used to treat rare diseases – for example, Orkambi and Kalydeco, two drugs brought to market by Vertex Pharmaceuticals. Both drugs are highly effective in treating certain variants of Cystic Fibrosis, a rare…

0 comments

In It for the Long Haul

Over the years, I have seen some pretty bad research come out of Wall Street. I remember an analyst recommending Akamai Technologies in 1980 right at the top. As it slid a heart stopping 20% in a few weeks, the analyst “re-iterated” his buy rating. He continued to be bullish and basically said it would…

0 comments

Pharmaceutical Distributors Feeling the Pain of U.S. Opioid Epidemic

Jay was lucky that Chera Kowalski knew about opioid overdoses and was trained to administer Naloxone (aka Narcan), the “antidote” for opioid overdose. Given that Opioid prescriptions have quadrupled since 1999, it’s hardly surprising that Jay’s situation is repeated over 1000 times each and every day in the United States alone. To be sure, there…

0 comments

The Generational Test for Investing….

One of the simplest techniques to help determine investment merit was actually made by a co-worker of mine. A couple of colleagues and I were discussing investment styles and strategies that had served them well over the years. One was oriented to short-term speculation and trading, another had a longer-term perspective (that would be me).…

0 comments